|
|
1.
|
Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus. MedStar authors:
Year: 2017
Citation: - Clinical Transplantation. 31(5), 2017 May
Institution: - MedStar Washington Hospital Center
Medline publication type:
All authors: - Hassan M, Lalos A, Liriano-Ward L, Morales AL, Nair V, Sang M, Satoskar R, Schiano T, Smith C, Tierney A
|
|
|
2.
|
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. MedStar authors:
Year: 2021
Citation: - Hepatology. 74(6):2952-2964, 2021 12.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Darling JM, Di Bisceglie A, Dong M, Evon DM, Fishbein DA, Fried MW, Hinestrosa F, Horne PM, Khalili M, Kixmiller S, Lok AS, Michael L, Moon JS, Morelli G, Muir AJ, Nelson DR, Pearlman B, Peter J, PRIORITIZE Study Team, Rajender Reddy K, Segal JB, Sherman KE, Shiffman ML, Sloan A, Stewart PW, Sulkowski MS, Vainorius M, Wadsworth S
|
